- Home
- CRGY vs SUPN Comparison
CRGY vs SUPN Comparison
Compare CRGY & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGY
- SUPN
- Stock Information
- Founded
- CRGY 1986
- SUPN 2005
- Country
- CRGY United States
- SUPN United States
- Employees
- CRGY N/A
- SUPN N/A
- Industry
- CRGY Oil & Gas Production
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- CRGY Energy
- SUPN Health Care
- Exchange
- CRGY Nasdaq
- SUPN Nasdaq
- Market Cap
- CRGY 2.5B
- SUPN 1.8B
- IPO Year
- CRGY N/A
- SUPN 2012
- Fundamental
- Price
- CRGY $9.29
- SUPN $33.18
- Analyst Decision
- CRGY Buy
- SUPN Hold
- Analyst Count
- CRGY 12
- SUPN 2
- Target Price
- CRGY $16.40
- SUPN $36.00
- AVG Volume (30 Days)
- CRGY 3.2M
- SUPN 790.6K
- Earning Date
- CRGY 08-04-2025
- SUPN 08-05-2025
- Dividend Yield
- CRGY 5.16%
- SUPN N/A
- EPS Growth
- CRGY N/A
- SUPN N/A
- EPS
- CRGY N/A
- SUPN 1.11
- Revenue
- CRGY $3,223,618,000.00
- SUPN $667,997,000.00
- Revenue This Year
- CRGY $25.73
- SUPN N/A
- Revenue Next Year
- CRGY N/A
- SUPN $12.02
- P/E Ratio
- CRGY N/A
- SUPN $29.94
- Revenue Growth
- CRGY 31.58
- SUPN 11.82
- 52 Week Low
- CRGY $6.83
- SUPN $26.65
- 52 Week High
- CRGY $16.94
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- CRGY 52.90
- SUPN 60.49
- Support Level
- CRGY $8.96
- SUPN $31.35
- Resistance Level
- CRGY $9.56
- SUPN $33.80
- Average True Range (ATR)
- CRGY 0.38
- SUPN 0.92
- MACD
- CRGY 0.02
- SUPN 0.16
- Stochastic Oscillator
- CRGY 67.26
- SUPN 79.12
About CRGY Crescent Energy Company
Crescent Energy Co is an independent energy company with a portfolio of assets in key basins across the lower 48 states. The company maintains a diverse portfolio of assets in key basins across the United States, including the Eagle Ford, Rockies, Barnett, Permian, and Mid-Con. It seeks to deliver attractive risk-adjusted investment returns and predictable cash flows across cycles with a focus on operated oil and gas assets complemented by non-operated assets, mineral and royalty interests, and midstream infrastructure.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.